Purpose Real-world studies have reported reduced mortality in patients with idiopathic
pulmonary fibrosis (IPF) treated with antifibrotic therapy; however, the initiation or …

Background: Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are
scarce, outside of registries. The claims data from the French National Health System …

In addition to facilitating healthcare delivery planning, reliable information about prognosis is
essential for treatment decisions in patients with idiopathic pulmonary fibrosis (IPF). This …

Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung
disease associated with significant morbidity and mortality. Nintedanib and pirfenidone are …

Background There are substantial advances in diagnosis and treatment for idiopathic
pulmonary fibrosis (IPF), but without much evidence available on recent mortality and …

Rationale: FVC has emerged as a standard primary endpoint in clinical trials evaluating
novel therapies for patients with idiopathic pulmonary fibrosis (IPF). However, it has recently …

In patients with idiopathic pulmonary fibrosis (IPF), the effects of antifibrotic agents on the
prognosis remain unclear. This study aimed to investigate the impact of antifibrotic treatment …

Objective There is a paucity of observational data on antifibrotic therapy for idiopathic
pulmonary fibrosis (IPF). We aimed to assess the course of disease of IPF patients with and …

Background: Idiopathic pulmonary fibrosis (IPF) is the most common and severe form of
idiopathic interstitial pneumonia, and its prevalence increases with age. In the era of pre …

Rationale: In recent decades, diagnosis and treatment recommendations for idiopathic
pulmonary fibrosis (IPF) have changed. In Korea, the average life expectancy has increased …